Finance

Beta
Lists
LONA:NASDAQ
LeonaBio Inc
$9.65
+0.10%
(+0.010) 1D
May 29, 10:15:38 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LONA...
Open
$9.65
High
$9.65
Low
$9.65
Mkt. cap
90.65M
Avg. vol.
42.10K
Volume
683.00
52-wk high
$14.21
52-wk low
$4.21
EPS
-$20.70
Beta
1.98
Shares outstanding
9.39M
No. of employees
19
Open
$9.65
High
$9.65
Low
$9.65
Mkt. cap
90.65M
Avg. vol.
42.10K
Volume
683.00
52-wk high
$14.21
52-wk low
$4.21
EPS
-$20.70
Beta
1.98
Shares outstanding
9.39M
No. of employees
19
News stories
From sources across the web
Profile
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors. Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
About LeonaBio Inc
CEO-
Employees19
Founded2011
HeadquartersBothell, Washington, United States
SectorPharmaceutical industry
Websiteleonabio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
3.66M
2.82M
6.71M
11.26M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.63M
4.05M
3.76M
6.88M
Operating expense
7.29M
6.87M
10.48M
18.14M
Total operating expenses
7.29M
6.87M
10.48M
18.14M
Operating income
-7.29M
-6.87M
-10.48M
-18.14M
Other non operating income
325.00K
263.00K
-4.39M
-14.80M
EBT including unusual items
-6.97M
-6.61M
-82.89M
-32.95M
EBT excluding unusual items
-6.97M
-6.61M
-14.87M
-32.95M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6.97M
-6.61M
-82.89M
-32.95M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.05M
-6.63M
-10.23M
-17.91M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer